NextPoint Therapeutics

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Frontier Medicines Corp. has raised $235.5m in venture capital to date, including an $80m series C round unveiled on 22 February, although this latest financing is slightly smaller than its $88.5m se

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an